Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | AKT1 | P31749 | 2/20 | 0.82 |
| ▸ | ESR1 | P03372 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | CDC25A | P30304 | 1/20 | 0.82 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | PRKCG | P05129 | 1/20 | 0.60 |
| ▸ | PRKCB | P05771 | 1/20 | 0.60 |
| ▸ | PRKCA | P17252 | 1/20 | 0.60 |
| ▸ | PRKCH | P24723 | 1/20 | 0.60 |
| ▸ | PRKCI | P41743 | 1/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elaidylphosphocholine SCHEMBL10415339 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Erufosine SCHEMBL4064798 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Erufosine SCHEMBL18343547 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL23016704 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Elaidylphosphocholine SCHEMBL18952927 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL23016878 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL21094307 | 0.94 | LMNA (0.72) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10937575 | 0.92 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10934199 | 0.92 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL30008220 | 0.92 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710927-A1 | OLEYLPHOSPHOCHOLINE IN THE TREATMENT OF LEISHMANIASIS | Oblita Therapeutics BVBA (BE) | 2026-03-18 | — | — | EP | claimed |
| US-12214081-B2 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2025-02-04 | — | — | US | claimed |
| EP-3965739-B1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2024-07-10 | — | — | EP | claimed |
| US-20220183975-A1 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2022-06-16 | — | — | US | claimed |
| EP-3965739-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | Oblita Therapeutics BVBA (BE) | 2022-03-16 | — | — | EP | claimed |
| WO-2020208230-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2020-10-15 | — | — | WO | claimed |
| EP-2680857-B1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | OBLITA THERAPEUTICS BVBA (BE) | 2019-04-24 | — | — | EP | claimed |
| EP-2642981-B1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2017-05-17 | — | — | EP | claimed |
| US-9358244-B2 | Solid dosage forms of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2016-06-07 | — | — | US | claimed |
| EP-2136816-B1 | OLEYL PHOSPHOCHOLINE | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2014-12-31 | — | — | EP | claimed |
| US-20140193493-A1 | Solid Dosage Forms of Oleyl Phosphocholine | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2014-07-10 | — | — | US | claimed |
| US-20130345177-A1 | Oleyl Phosphocholine for the Treatment of Mycosis | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2013-12-26 | — | — | US | claimed |
| EP-2663282-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION | Dafra Pharma Research & Development BVBA (BE) | 2013-11-20 | — | — | EP | claimed |
| US-20130296277-A1 | Pharmaceutical Compositions for the Treatment of Parasitic Diseases, Cancer, or Skin Diseases by Topical Administration | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2013-11-07 | — | — | US | claimed |
| EP-2642981-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | Dafra Pharma Research & Development BVBA (BE) | 2013-10-02 | — | — | EP | claimed |
| WO-2012119870-A1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-09-13 | — | — | WO | claimed |
| WO-2012095500-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-07-19 | — | — | WO | claimed |
| WO-2012069427-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-05-31 | — | — | WO | claimed |
| US-20100144676-A1 | OLEYL PHOSPHOCHOLINE | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-06-10 | — | — | US | claimed |
| EP-0108565-A2 | Phospholipids, their production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1984-05-16 | — | — | EP | claimed |